We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Stahl, SM. Antidepressant treatment of psychotic major depression: potential role of the σ receptor. CNS Spectr. 2005;10:519–523.CrossRefGoogle ScholarPubMed
2
2.Levkovitz, Y, Bloch, Y, Kaplan, D, Diskin, A, Abramovitchi, I. Fluvoxamine for psychosis in Alzheimer's disease. J Nerv Ment Dis. 2001;189:126–129.Google Scholar
1
1.Stahl, SM. Antidepressant treatment of major depression: potential role of the σ receptor. CNS Spectr2005;10:319–323.Google Scholar
2
2.Stahl, SM. Not so selective serotonin reuptake inhibitors. J Clin Psychiatry. 1998;59:343–344.Google ScholarPubMed
3
3.Stahl, SM. Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. J Clin Psychiatry. 1998;59:642–643.CrossRefGoogle Scholar
4
4.Stahl, SM. Selectivity of SSRIs: individualizing patient care through rational treatment choices. Int J Psy Clin Prac. 2004;8(suppl 1):3–10.CrossRefGoogle ScholarPubMed
5
5.Stahl, SM. Let them eat generics: can one atypical antipsychotic substitute for another?PsychEd Up. 2005;1:6–7.Google Scholar
6
6.Stahl, SM, Shayegan, DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64(suppl 19):6–12.Google ScholarPubMed
7
7.Shayegan, DK, Stahl, SM. Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. CNS Spectr. 2004;9(suppl 11):6–14.CrossRefGoogle ScholarPubMed